{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:42:40Z","timestamp":1761493360705,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004734","name":"Jewish General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jcjd.2019.08.004","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T17:12:52Z","timestamp":1565889172000},"page":"5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to the Letter to the Editor From Dr Kawada, \u201cAngiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus\u201d"],"prefix":"10.1016","volume":"44","author":[{"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-2822","authenticated-orcid":false,"given":"Mark L.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2019.08.004_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcjd.2017.11.006","article-title":"Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers for the treatment of hypertension in adults with type 2 diabetes: Why we favour angiotensin receptor blockers","volume":"42","author":"Mavrakanas","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2019.08.004_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jcjd.2019.01.001","article-title":"Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors for the treatment of hypertensive patients with type 2 diabetes mellitus","volume":"44","author":"Kawada","year":"2020","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2019.08.004_bib3","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2019.08.004_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14740\/jocmr3744","article-title":"Association between the use of thiazide diuretics and the risk of skin cancers: A meta-analysis of observational studies","volume":"11","author":"Shin","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jcjd.2019.08.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","article-title":"Anti-hypertensive drugs and skin cancer risk: A review of the literature and meta-analysis","volume":"122","author":"Gandini","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267119305945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267119305945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:34:50Z","timestamp":1761492890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267119305945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1499267119305945"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2019.08.004","relation":{},"ISSN":["1499-2671"],"issn-type":[{"type":"print","value":"1499-2671"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to the Letter to the Editor From Dr Kawada, \u201cAngiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus\u201d","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2019.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2019.01.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Diabetes Association.","name":"copyright","label":"Copyright"}]}}